Kyungdong Pharm Co., Ltd. (011040) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Kyungdong Pharm Co., Ltd. (011040:KRX), powered by AI.

Current Price
₩5,230
P/E Ratio
18.9
Market Cap
160.9B
Sector
Common Stock
What is the Kyungdong Pharm Co., Ltd. stock price forecast?

Kyungdong Pharm Co., Ltd. is currently trading at ₩5,230. View real-time AI analysis on Alpha Lenz.

What is Kyungdong Pharm Co., Ltd. insider trading activity?

View the latest insider trading data for Kyungdong Pharm Co., Ltd. on Alpha Lenz.

What is Kyungdong Pharm Co., Ltd.'s P/E ratio?

Kyungdong Pharm Co., Ltd.'s P/E ratio is 18.9.

Kyungdong Pharm Co., Ltd.

KRX · 011040
₩5,230-10(-0.19%)Market closedKRX regular session 09:00–15:30 KST
Ask about Kyungdong Pharm Co., Ltd.'s future dividend policy...
Alpha Chat Insight

Kyungdong Pharm Co., Ltd. trades at a P/E of 18.9 (fair value) with modest ROE of 3.8%.

Ask for details

Company Overview

Kyungdong Pharm Co., Ltd. is a prominent entity in the pharmaceutical industry, primarily engaged in the research, development, and distribution of various medicinal products. As a key player in the healthcare sector, Kyungdong Pharm focuses on creating high-quality prescription drugs, over-the-counter medications, and other health-related consumer goods, catering to a broad spectrum of therapeutic areas. The company enhances its market presence through a commitment to innovation and adherence to rigorous quality standards, ensuring the efficacy and safety of its pharmaceutical offerings. Founded in South Korea, it plays a vital role in meeting the healthcare needs both domestically and in international markets. Kyungdong Pharm is active in partnerships and collaborations with scientific institutions and hospitals that help advance its research capabilities and expand its global footprint. As part of the competitive pharmaceutical market, the company contributes significantly to advancements in medical treatments, positioning itself as a reliable source of healthcare solutions. Its strategic initiatives and robust product portfolio underline its importance in providing essential health care products to a diverse clientele.

CEO류기성, 김경훈(각자 대표)
SectorCommon Stock
IndustryCommon Stock
0

Company Statistics

FY 2025

Profile

₩160,920,646,180Market Cap
₩196,273,042,780Revenue
30.77MShares Out
0Employees

Margins

59.69%Gross
8.27%EBITDA
3.91%Operating
4.65%Pre-Tax
4.31%Net

Valuation

18.87P/E
0.70P/B
0.82EV/Sales
10.79EV/EBITDA
-44.97P/FCF

Growth (CAGR)

2.41%Rev 3Yr
2.46%Rev 5Yr
-2.66%Op Inc 3Yr
-18.41%Op Inc 5Yr
-11.31%Net Inc 3Yr
-8.07%Net Inc 5Yr

Returns

2.71%ROA
3.80%ROE
3.49%ROIC

Financial Health

₩31,809,394,930Cash & Cash Equivalents
₩61,212,969,740Net Debt
40.64%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Kyungdong Pharm Co., Ltd. (ticker: 011040) is a company listed on KRX in the Common Stock sector (Common Stock). Market cap is $160.9B.

The current price is ₩5,230 with a P/E ratio of 18.87x and P/B of 0.7x.

ROE is 3.80% and operating margin is 3.91%. Annual revenue is $196.3B.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Kyungdong Pharm Co., Ltd. (011040) Stock Forecast 2026 ₩5,230 — Price, Financials & Analyst Targets | Alpha Lenz